Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

19 Nov 2008 10:48

RNS Number : 4691I
British SmallerTechCompaniesVCT2PLC
19 November 2008
 

BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2008

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 30 September 2008. This constitutes the Company's second interim management statement for the financial year ending 31 December 2008, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.

The unaudited net asset value per Ordinary share as at 30 September 2008 was 79.7 pence. This is a decrease of 3.9% over the net asset value of 82.9 pence per share at 30 June 2008.  The reduction is largely attributed to the recognition of the special and interim dividend paid to shareholders in September and totalling 4 pence per share. Hence the total return, calculated by reference to the net asset value plus cumulative dividends paid has increased from 94.9p per share at 30 June 2008 to 95.7 pence per share at 30 September 2008, an increase of 0.8%.  

In addition to the dividend, the last three months have seen the value of the AiM portfolio depressed given the market conditions and a £94k reduction in the portfolio has been recognised.  This represents a 6% reduction in the value of the AiM portfolio during the quarter. A review of the unquoted portfolio has identified some ups and downs, but minimal net impact on the value of the unquoted portfolio overall. The reduction in the value of the AiM portfolio has been offset by the recovery in the market value of the gilts, which have increased £110k during the period. At 30 September 2008, the Company held cash and Gilts representing 42.5% of the net asset value. 

This quarter has seen the inclusion of £164,000 in respect of the reclaim for irrecoverable VAT in line with the ruling by HMRC.

There has been no movement in the number of Ordinary shares, 16,641,257 Ordinary shares being in issue at both 31 December 2007 and 30 June 2008.

The Company has completed one investment in the quarter, being a £52,000 follow on equity investment in Manchester based computer chip designer Silistix Limited Disposals of £3,500 related to the scheduled loan repayments made by RMS Group Limited.

Net assets at 30 September 2008 comprised the following:

£000

% of net assets

Unquoted investments at fair value

5,815

43.8

Quoted investments at bid price

1,519

11.5

Total venture capital investments

7,334

55.3

Cash and cash equivalents

5,633

42.5

Other net current assets

295

2.2

Net assets

13,262

100.0

The net asset value per Ordinary share at 30 September 2008 was 79.7 pence. The net asset value remains significantly in excess of the current share price.

The ten largest investments by valuation at 30 September 2008 were as follows:

£000

% of net assets

Digital Healthcare

1,650

12.5

Immunobiology

850

6.4

Silistix

719

5.4

Primal Pictures

642

4.8

Pressure Technologies

520

3.9

ART

484

3.7

RMS

435

3.3

Cater Plus

345

2.6

DxS

320

2.4

Harvey Jones

278

2.1

Top ten investments

6,243

47.1

Other investments

1,091

8.2

Total venture capital investments

7,334

55.3

Quoted investments are carried at bid price at 30 September 2008. Unquoted investment are carried at fair value as at 30 September 2008 as determined by the directors.

During the three months ended 30 September 2008 the following significant investment transactions took place (all companies are unquoted except where otherwise indicated):

Follow-on Investments:

Name of company:

Business activity:

Amount invested £000

Silistix Ltd

Silicon chip design

52

52

In this period the Company has seen its underlying net asset value increase by 0.8 pence per share after the payment of an interim dividend of 2 pence per share and a special dividend of 2 pence share. It is pleasing to note that the residual net asset value has both increased and currently comprises 42.5% in gilts and cash.

With the principal investments in the portfolio all having secured funding with little exposure to financial leverage the portfolio is itself well placed to take advantage of expansion opportunities as they arise.

There has been a marked increase in the number of investment opportunities being presented. The Company's liquidity is good but your board will be seeking to increase this through a non-prospectus top up offer early in the New Year.

 

19 November 2008

For further information please contact:

David Hall YFM Private Equity Tel: 0161 832 7603

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUGMCGUPRGUB
Date   Source Headline
6th May 20267:00 amRNSDividend Declaration
20th Apr 202610:01 amRNSAdmission to Trading
1st Apr 20269:00 amRNSIssue of Equity
27th Mar 20264:12 pmRNSTransaction in Own Shares
23rd Mar 202610:45 amRNSPublication of a Supplementary Prospectus
19th Mar 20267:00 amRNSAnnual Financial Report
30th Jan 20267:00 amRNSAdmission of Further Securities to Trading
7th Jan 20269:31 amRNSDirector/PDMR Shareholding
7th Jan 20269:30 amRNSIssue of Equity
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
22nd Dec 20259:13 amRNSTransaction in Own Shares
22nd Dec 20259:13 amRNSTransaction in Own Shares
18th Dec 202512:14 pmRNSClose of Offers to new Applications
18th Dec 202512:14 pmRNSClose of Offers to new Applications
28th Nov 202510:00 amRNSInterim Management Statement
20th Nov 20259:00 amRNSOffer Update
31st Oct 202510:01 amRNSPayment of dividend and issue of Equity
10th Oct 20253:41 pmRNSOffer Update
2nd Oct 20259:00 amRNSOffer Update
25th Sep 20259:04 amRNSPublication of a Prospectus
23rd Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSHalf-year Report
22nd Aug 202510:45 amRNSNew combined offer for subscription
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 202510:20 amRNSPayment of Dividend and Issue of Equity
13th Jun 20251:30 pmRNSInterim Management Statement
12th Jun 202510:46 amRNSResult of AGM
13th May 202512:54 pmRNSDividend Declaration
1st Apr 20258:02 amRNSDirector/PDMR Shareholding
1st Apr 20258:00 amRNSIssue of Equity
26th Mar 20255:15 pmRNSTransaction in Own Shares
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
18th Mar 20251:00 pmRNSAnnual Financial Report
30th Jan 20259:05 amRNSDirector/PDMR Shareholding
30th Jan 20259:00 amRNSIssue of Equity
27th Jan 20259:21 amRNSPayment of dividend and issue of shares
8th Jan 20252:14 pmRNSClose of Offer to new Applications
8th Jan 20252:13 pmRNSClose of Offer to new Applications
17th Dec 20242:13 pmRNSNominal Capital Reduction
17th Dec 20247:00 amRNSDividend Declaration
16th Dec 20245:08 pmRNSTransaction in Own Shares
29th Nov 20249:00 amRNS3rd Quarter Results
20th Nov 20241:00 pmRNSOffer Update
20th Nov 20241:00 pmRNSOffer Update
12th Nov 20241:52 pmRNSResult of General Meeting
1st Nov 202411:04 amRNSPayment of Dividend and Allotment of Shares
1st Nov 20247:00 amRNSOffer Update
1st Nov 20247:00 amRNSOffer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.